Go to website
General information
Description
QMENTA is an advanced medical image storage, processing and visualization company focused on brain data analysis, specifically using MRI and related clinical data.
It provides state-of-the-art medical image processing algorithms transparently to accelerate the development of new therapies for neurological diseases through a scalable and collaborative cloud platform.
Foundation year
Year of company creation
2015
Headquarters
Headquarters
Barcelona
Offices
Offices in
Barcelona
Employees
11-50 employees
Level of internalization
Level of internalization
Spain, USA
Main products and services
Main products and services
QMENTA AI Reader can ensure the success of the trial by helping experts to choose patients at the right stage of the disease and qualitatively demonstrate the efficacy of the treatment during the course of the trial using QMENTA's state-of-the-art neurological AI algorithms.
It aims to save substantial time and resources for the sponsor and the CRO by automating the manual work of the experts, optimizing the use of resources and minimizing the burden on the site. QMENTA AI Reader offers tools for diagnosis, prognosis, monitoring, and decision support for experts and physicians, freeing up their time by automating manual tasks and extracting valuable information from raw images to facilitate decision making.
QMENTA's neuro IA tools provide a unique view of brain anatomy by accentuating tissue change or damage or hyperintensities in colour and 3D, and by creating maps of the brain network to see changes in connections due to disease or injury. These state-of-the-art algorithms, driven by deep, machine learning, help clinicians accurately assess patients and their disease status based on objective criteria.
Key to success
Key to success
His vision is to live in a world where brain diseases can be cured or prevented, a world where brain diseases are a thing of the past.
Its mission is to organize and quantify brain imaging information through advanced imaging tools and deliver it to experts in a transparent manner.
Its goal is to change the way patients are diagnosed and monitored, and to measure disease progression and drug efficacy; to date, this represents one of the greatest health challenges for aging societies in the world.
Growth
Growth
The turnover is expected to grow to 100M euros per year in 5 years.
Future plans
Future plans
Strong investment in R&D.
Data used
Open data used
It mainly uses private data, but in the last months they have incorporated open data related to COVID-19.
Clients
Customers
Hospitals, clinics, pharmaceutical companies
Marketing model
Marketing model
They market their products and services directly, through pay-per-use and subscription models.
Content provided by the reuse company.
The content and opinions shown in this publication are the exclusive responsibility of the author.